In addition, identified LHR-blocking candidates may be examined for potential relevance for health issues such as Alzheimer’s disease and certain malignancies (e.g., prostate cancer), where a non-classical involvement of LH/CG was reported [59,60,61,62,63,64,65,66,67,68]. Here, PLOD1 is linked to prostate carcinoma.